<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39434522</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0004-1955</ISSN><JournalIssue CitedMedium="Print"><Volume>86</Volume><Issue>5</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Arkhiv patologii</Title><ISOAbbreviation>Arkh Patol</ISOAbbreviation></Journal><ArticleTitle>[ALDH1, CD133, CD34-positive cancer stem cells in lung adenocarcinoma in patients who had a new coronavirus infection and retained the persistence of viral proteins in the lung tissue].</ArticleTitle><Pagination><StartPage>5</StartPage><EndPage>14</EndPage><MedlinePgn>5-14</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.17116/patol2024860515</ELocationID><Abstract><AbstractText Label="UNLABELLED">Lung cancer occupies a leading position in the structure of global cancer morbidity and mortality, due to the biological properties of the key pool of tumor cells - cancer stem cells (CSCs). The effects of SARS-CoV2 on tumor CSCs and its niche have not been studied.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To study CSCs in lung adenocarcinomas after COVID19.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">Surgical material from lung adenocarcinoma from 12 patients who had a new coronavirus infection and from 12 patients who did not have COVID19 was examined. Analysis of clinical and anamnestic data, macroscopic and microscopic examination of tumor samples and adjacent intact tissue, immunohistochemical reactions using antibodies to virus proteins and CSC markers ALDH1, CD133 and CD34 were performed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Adenocarcinoma samples from patients in the main group showed a significant increase in the number of cells expressing the CSCs markers ALDH1, CD133 and CD34 compared to adenocarcinoma samples from control group patients without SARS-CoV2 infection. We found an increase in the number of CSCs in patients with adenocarcinoma metastasis in lymph nodes in both the main and control groups. CSCs of lung adenocarcinomas from SARS-CoV2 survivors contain virus proteins Nucleocapside and Spike protein.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We found an increase in the number of CSCs with expression of ALDH1, CD133 and CD34 in lung adenocarcinoma in patients with new coronavirus infection. Increased number of ALDH1+, CD133+ CD34+ CSCs in tumor tissue enhance the metastatic potential of lung adenocarcinoma. The Nucleocapsid and Spike proteins of SARS-CoV2 virus are detectable in lung tissue from patients with new coronavirus infection, both in adenocarcinoma cells, CSCs, and in type II pneumocytes, macrophages, and endothelial cells, suggesting prolonged persistence of the virus proteins and probably the virus.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kogan</LastName><ForeName>E A</ForeName><Initials>EA</Initials><Identifier Source="ORCID">0000-0002-1107-3753</Identifier><AffiliationInfo><Affiliation>I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shchelokova</LastName><ForeName>E E</ForeName><Initials>EE</Initials><Identifier Source="ORCID">0000-0002-5030-0429</Identifier><AffiliationInfo><Affiliation>I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demura</LastName><ForeName>T A</ForeName><Initials>TA</Initials><Identifier Source="ORCID">0000-0002-6946-6146</Identifier><AffiliationInfo><Affiliation>I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zharkov</LastName><ForeName>N V</ForeName><Initials>NV</Initials><Identifier Source="ORCID">0000-0001-7183-0456</Identifier><AffiliationInfo><Affiliation>I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kichigina</LastName><ForeName>O N</ForeName><Initials>ON</Initials><Identifier Source="ORCID">0009-0009-0013-3587</Identifier><AffiliationInfo><Affiliation>I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kovyazina</LastName><ForeName>N V</ForeName><Initials>NV</Initials><Identifier Source="ORCID">0009-0005-9889-1378</Identifier><AffiliationInfo><Affiliation>Russian University of Medicine, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mordovina</LastName><ForeName>A I</ForeName><Initials>AI</Initials><Identifier Source="ORCID">0000-0002-5700-6505</Identifier><AffiliationInfo><Affiliation>I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zelenchenkova</LastName><ForeName>P I</ForeName><Initials>PI</Initials><Identifier Source="ORCID">0000-0002-9491-318X</Identifier><AffiliationInfo><Affiliation>I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meerovich</LastName><ForeName>G A</ForeName><Initials>GA</Initials><Identifier Source="ORCID">0000-0002-2046-5492</Identifier><AffiliationInfo><Affiliation>I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>A.M. Prokhorov General Physics Institute Russian Academy of Sciences (GPI RAS), Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reshetov</LastName><ForeName>I V</ForeName><Initials>IV</Initials><Identifier Source="ORCID">0000-0002-0909-6278</Identifier><AffiliationInfo><Affiliation>I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>rus</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>ALDH1-, CD133-, CD34-pozitivnye rakovye stvolovye kletki v adenokartsinome legkogo u patsientov, perenesshikh novuyu koronavirusnuyu infektsiyu SARS-CoV2.</VernacularTitle></Article><MedlineJournalInfo><Country>Russia (Federation)</Country><MedlineTA>Arkh Patol</MedlineTA><NlmUniqueID>0370604</NlmUniqueID><ISSNLinking>0004-1955</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071916">AC133 Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.2.1</RegistryNumber><NameOfSubstance UI="D000080924">Aldehyde Dehydrogenase 1 Family</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.2.1.36</RegistryNumber><NameOfSubstance UI="C510223">ALDH1A1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018952">Antigens, CD34</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.2.1.36</RegistryNumber><NameOfSubstance UI="D050697">Retinal Dehydrogenase</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606023">PROM1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014411" MajorTopicYN="Y">Neoplastic Stem Cells</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071916" MajorTopicYN="Y">AC133 Antigen</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008175" MajorTopicYN="Y">Lung Neoplasms</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077192" MajorTopicYN="Y">Adenocarcinoma of Lung</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000080924" MajorTopicYN="Y">Aldehyde Dehydrogenase 1 Family</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018952" MajorTopicYN="Y">Antigens, CD34</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050697" MajorTopicYN="Y">Retinal Dehydrogenase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="rus"><AbstractText Label="UNLABELLED">Рак легкого занимает лидирующие позиции в структуре мировой онкологической заболеваемости и смертности, что обусловлено биологическими свойствами ключевого пула клеток опухоли — раковых стволовых клеток (РСК). Последствия воздействия SARS-CoV2 на РСК опухоли и ее нишу не изучены.</AbstractText><AbstractText Label="ЦЕЛЬ ИССЛЕДОВАНИЯ" NlmCategory="UNASSIGNED">Изучение РСК в аденокарциномах легкого после перенесенного COVID-19.</AbstractText><AbstractText Label="МАТЕРИАЛ И МЕТОДЫ" NlmCategory="UNASSIGNED">Исследован операционный материал аденокарциномы легкого 12 пациентов, перенесших новую коронавирусную инфекцию, и 12 пациентов, не болевших COVID-19. Проводились анализ клинико-анамнестических данных, макроскопическое и микроскопическое исследование образцов опухолей и прилежащей интактной ткани, ставились иммуногистохимические реакции с использованием антител к белкам вируса и маркерам РСК — ALDH1, CD133 и CD34.</AbstractText><AbstractText Label="РЕЗУЛЬТАТЫ" NlmCategory="UNASSIGNED">Образцы аденокарцином пациентов основной группы демонстрировали существенное увеличение количества клеток, экспрессирующих маркеры стволовости ALDH1, CD133 и CD34 по сравнению с образцами аденокарцином пациентов контрольной группы, не болевших инфекцией SARS-CoV2. Установлено увеличение количества РСК у пациентов с метастазами аденокарциномы в лимфатических узлах как в основной, так и в контрольной группах. РСК аденокарцином легкого у лиц, переболевших SARS-CoV2, содержат белки вируса Nucleocapside и Spike-белок.</AbstractText><AbstractText Label="ВЫВОДЫ" NlmCategory="UNASSIGNED">Установлено увеличение количества РСК с экспрессией маркеров стволовости ALDH1, CD133 и CD34 в аденокарциноме легкого у пациентов, перенесших новую коронавирусную инфекцию. Увеличение количества ALDH1+, CD133+ CD34+ РСК в опухолевой ткани повышает метастатический потенциал аденокарциномы легкого. Нуклеокапсидный и спайк-белки вируса SARS-CoV2 обнаруживаются в ткани легкого у пациентов, перенесших новую коронавирусную инфекцию, как в клетках аденокарциномы, РСК опухоли, так и в пневмоцитах II типа, макрофагах и эндотелиальных клетках, что говорит о длительной персистенции белков вируса и, вероятно, вируса.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALDH1</Keyword><Keyword MajorTopicYN="N">CD133</Keyword><Keyword MajorTopicYN="N">CD34</Keyword><Keyword MajorTopicYN="N">COVID19</Keyword><Keyword MajorTopicYN="N">PDT</Keyword><Keyword MajorTopicYN="N">cancer progression</Keyword><Keyword MajorTopicYN="N">cancer stem cells</Keyword><Keyword MajorTopicYN="N">carcinogenesis</Keyword><Keyword MajorTopicYN="N">lung adenocarcinoma</Keyword><Keyword MajorTopicYN="N">persistence of Nucleocapside and Spike proteins of SARS-CoV2 in lung tissue</Keyword><Keyword MajorTopicYN="N">persistence of SARS-CoV2 virus in lung tissue</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>2</Hour><Minute>35</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39434522</ArticleId><ArticleId IdType="doi">10.17116/patol2024860515</ArticleId></ArticleIdList></PubmedData></PubmedArticle>